Reprogramming of mature SMCs to vascular progenitor cells: Focus on Vascular Fibrosis
Reprogramming of mature SMCs to vascular progenitor cells: Focus on Vascular Fibrosis
批准号:
10675281
负责人:
MARK W. MAJESKY
金额:
$77.21万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-01-18 至 2027-06-30
关键词:
AcomysAcuteAdultAtherosclerosisBlood VesselsCell Differentiation processCell MaintenanceCell ReprogrammingCell modelCellsChronicCoronary arteryCultured CellsCytometryDatabasesDepositionDevelopmentDiseaseEpigenetic ProcessExtracellular MatrixExtracellular Matrix ProteinsFibrosisGene Expression ProfileGenesGeneticHDAC1 geneHumanImmuneIn SituIn VitroInflammationInjury to KidneyKnock-outMaintenanceMammalsMapsMesenchymalModelingMolecularMusMyofibroblastNatural regenerationNormal tissue morphologyPathologicPathway interactionsPatientsPerivascular FibrosisPhenotypePlayPopulationPreventionProcessProfibrotic signalProteinsProteomeProteomicsRNARegulationReporterReportingRepressionResistanceRodentRoleSignal TransductionSmooth Muscle MyocytesSourceSystemTherapeutic StudiesTissuesTranscriptTunica AdventitiaValidationVascular DiseasesVascular Smooth MuscleVascular remodelingclinical applicationcohortgenetic signaturemouse modelnoveloverexpressionprogenitorpublic health relevanceregenerativeresponsesingle-cell RNA sequencingstem cellsstemnesstissue repairtranscription factortranscriptome sequencingtranscriptomicsvascular injurywound healing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Excessive perivascular fibrosis results from the highly dynamic and dysregulated process of normal tissue repair
and is defined by the excessive accumulation of extracellular matrix (ECM) material resulting in decreased
vascular compliance and increased vessel stiffness. In contrast, a fibrotic response is critical to the formation
and stability of a fibrous cap in the setting of atherosclerosis. While advances have been made in our
understanding of fibrosis pathobiology, significant gaps remain. In particular, while mesenchymal cells with the
potential to transition into activated myofibroblasts are believed to be key sources of excessive ECM deposition,
their origin remain debated. Using cell-specific lineage tracing and RNA sequencing, our group made the
paradigm-shifting discovery that a subpopulation of resident vascular stem cells residing within the vascular
adventitia originate from mature vascular smooth muscle cells (SMC)(termed AdvSca1-SM cells). SMC
reprogramming and AdvSca1-SM cell maintenance is dependent on induction and activity of the transcription
factor, Klf4. In contrast, vascular injury-induced or AdvSca1-SM cell-specific genetic Klf4 depletion promote the
transition to profibrotic myofibroblasts, which consequently serve as major contributors to perivascular fibrosis.
However, the molecular mechanism whereby Klf4 dictates the maintenance and differentiation of AdvSca1-SM
cells remains unclear. Leveraging a highly specific AdvSca1-SM cell reporter system and single-cell RNA-
sequencing (scRNA-seq), we demonstrate the profibrotic differentiation trajectory of AdvSca1-SM cells.
Differentiation is characterized by loss of Klf4 and its downstream effector PI16, a negative regulator of the
epigenetic protein, histone deacetylase 1 (HDAC1), and the lncRNA, Meg3, but gain of expression of a profibrotic
phenotype. Importantly, these changes were recapitulated in human fibrotic tissue, underlying the translational
significance. Statin treatment was previously shown to reduce tissue fibrosis; however, the molecular mechanism
is unknown. Querying Connectivity Map database with gene signatures of AdvSca1-SM cells and their profibrotic
derivatives indicate that statins are potential candidates to antagonize the profibrotic transition of AdvSca1-SM
cells. Finally, while inflammation and fibrosis drive the wound healing process in most adult mammals, scarless
regenerative wound healing in adult rodents of the species Acomys has been reported. Our recent findings show
a complete absence of fibrosis with rapid regeneration in two models of kidney injury in Acomys. Here, we
propose a novel concept that a Klf4-Meg3 axis plays a central role in the maintenance of the stem cell phenotype;
loss of Klf4 and/or Meg3 activates a signaling cascade facilitating the phenotypic transition of AdvSca1-SM (Aim
One). Further, we propose that Acomys is resistant to pathological vascular remodeling and fibrosis in part due
to activation of an AdvSca1-SM-specific regenerative gene expression signature (Aim Two). Finally, statin
treatment will inhibit or reverse the profibrotic transition of AdvSca1-SM cells (Aim Three).
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1161/circulationaha.121.058173
发表时间:
2022-03-29
期刊:
CIRCULATION
影响因子:
37.8
作者:
[Sawada, Hisashi, Katsumata, Yuriko, Higashi, Hideyuki, Zhang, Chen, Li, Yanming, Morgan, Stephanie, Lee, Lang H., Singh, Sasha A., Chen, Jeff Z., Franklin, Michael K., Moorleghen, Jessica J., Howatt, Deborah A., Rateri, Debra L., Shen, Ying H., LeMaire, Scott A., Aikawa, Masanori, Majesky, Mark W., Lu, Hong S., Daugherty, Alan]
通讯作者:
Daugherty, Alan
Nuclear Focal Adhesion Kinase.
核焦点粘附激酶。
DOI:
10.1161/circresaha.119.315395
发表时间:
2019
期刊:
Circulation research
影响因子:
20.1
作者:
[Lu,Sizhao, Weiser-Evans,MaryCM]
通讯作者:
Weiser-Evans,MaryCM
DOI:
10.3389/fnagi.2018.00210
发表时间:
2018
期刊:
Frontiers in aging neuroscience
影响因子:
4.8
作者:
[Berthiaume AA, Hartmann DA, Majesky MW, Bhat NR, Shih AY]
通讯作者:
Shih AY
DOI:
10.12688/f1000research.15994.1
发表时间:
2018-12
期刊:
F1000Research
影响因子:
--
作者:
[S. Schwartz;R. Virmani;M. Majesky]
通讯作者:
S. Schwartz;R. Virmani;M. Majesky
DOI:
10.1161/atvbaha.118.310223
发表时间:
2018-03
期刊:
Arteriosclerosis, thrombosis, and vascular biology
影响因子:
--
作者:
[Majesky MW]
通讯作者:
Majesky MW
共 8 条
Reprogramming of mature smooth muscle cells to vascular progenitor cells
-
批准号:10326381
-
项目类别:
-
资助金额:$63.76万
-
财政年份:2019
-
负责人:MARK W. MAJESKY
-
依托单位:
Reprogramming of mature smooth muscle cells to vascular progenitor cells
-
批准号:10077570
-
项目类别:
-
资助金额:$63.76万
-
财政年份:2019
-
负责人:MARK W. MAJESKY
-
依托单位:
Resident Progenitor Cells in the Adventitia
-
批准号:8898210
-
项目类别:
-
资助金额:$61.7万
-
财政年份:2014
-
负责人:MARK W. MAJESKY
-
依托单位:
Resident Progenitor Cells in the Adventitia
-
批准号:9099913
-
项目类别:
-
资助金额:$62.64万
-
财政年份:2014
-
负责人:MARK W. MAJESKY
-
依托单位:
Resident Progenitor Cells in the Adventitia
-
批准号:9276100
-
项目类别:
-
资助金额:$50.98万
-
财政年份:2014
-
负责人:MARK W. MAJESKY
-
依托单位:
Resident Progenitor Cells in the Adventitia
-
批准号:8751603
-
项目类别:
-
资助金额:$64.95万
-
财政年份:2014
-
负责人:MARK W. MAJESKY
-
依托单位:
Hedgehog Signaling in the Adventitia
-
批准号:8299069
-
项目类别:
-
资助金额:$48.26万
-
财政年份:2009
-
负责人:MARK W. MAJESKY
-
依托单位:
Hedgehog Signaling in the Adventitia
-
批准号:7735831
-
项目类别:
-
资助金额:$36.56万
-
财政年份:2009
-
负责人:MARK W. MAJESKY
-
依托单位:
Hedgehog Signaling in the Adventitia
-
批准号:8118158
-
项目类别:
-
资助金额:$48.75万
-
财政年份:2009
-
负责人:MARK W. MAJESKY
-
依托单位:
Hedgehog Signaling in the Adventitia
-
批准号:7894964
-
项目类别:
-
资助金额:$48.75万
-
财政年份:2009
-
负责人:MARK W. MAJESKY
-
依托单位:
Development of Coronary Smooth Muscle
-
批准号:7541723
-
项目类别:
-
资助金额:$38.26万
-
财政年份:2008
-
负责人:MARK W. MAJESKY
-
依托单位:
Development of Coronary Smooth Muscle
-
批准号:7333211
-
项目类别:
-
资助金额:$37.91万
-
财政年份:2007
-
负责人:MARK W. MAJESKY
-
依托单位:
Development of Coronary Smooth Muscle
-
批准号:7312434
-
项目类别:
-
资助金额:$36.62万
-
财政年份:2006
-
负责人:MARK W. MAJESKY
-
依托单位:
Development of Coronary Smooth Muscle
-
批准号:6967719
-
项目类别:
-
资助金额:$37.92万
-
财政年份:2005
-
负责人:MARK W. MAJESKY
-
依托单位:
SYMPATHETIC TROPHIC EFFECTS ON ARTERIAL SMOOTH MUSCLE
-
批准号:2223837
-
项目类别:
-
资助金额:$16.73万
-
财政年份:1992
-
负责人:MARK W. MAJESKY
-
依托单位:
SYMPATHETIC TROPHIC EFFECTS ON ARTERIAL SMOOTH MUSCLE
-
批准号:2223836
-
项目类别:
-
资助金额:$16.07万
-
财政年份:1992
-
负责人:MARK W. MAJESKY
-
依托单位:
SYMPATHETIC TROPHIC EFFECTS ON ARTERIAL SMOOTH MUSCLE
-
批准号:2223838
-
项目类别:
-
资助金额:$17.39万
-
财政年份:1992
-
负责人:MARK W. MAJESKY
-
依托单位:
SYMPATHETIC TROPHIC EFFECTS ON ARTERIAL SMOOTH MUSCLE
-
批准号:3366892
-
项目类别:
-
资助金额:$15.41万
-
财政年份:1992
-
负责人:MARK W. MAJESKY
-
依托单位:
SYMPATHETIC TROPHIC EFFECTS ON ARTERIAL SMOOTH MUSCLE
-
批准号:3366891
-
项目类别:
-
资助金额:$15.93万
-
财政年份:1992
-
负责人:MARK W. MAJESKY
-
依托单位:
Experimental Pathology of Cardiovascular Disease
-
批准号:8793027
-
项目类别:
-
资助金额:$67.72万
-
财政年份:1978
-
负责人:MARK W. MAJESKY
-
依托单位:
海外基金